Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biden’s Vaccine Donation Plan Emphasizes American Production, Not IP Waivers

Executive Summary

President announces ‘new effort’ to work with pharmaceutical companies, other nations to increase supply. Details remain in short supply, but Biden says plan will increase domestic production capacity to prepare ‘the next crises.’

You may also be interested in...



Research Industry Presents United Front On Japan Reforms

Three groups representing the domestic and multinational research-based pharma industry in Japan present a unified position as they call for policy changes they see as providing the right environment for investment, innovation and a sustainable healthcare system. 

US COVID Vaccine Patent Waiver Is Big, Symbolic Blow For Pharma, But The Fight Is Just Beginning

Drug manufacturers still have a variety of ways to limit the impact of the Biden administration’s historic decision. Whether the huge political loss for industry translates into more than just headline-risk or faster global COVID vaccination remains to be seen. It's also not clear whether it’s an ominous sign for other industry battles in the US, including the drug pricing debate.

Of Patents And Production: Industry-White House Row Over Vaccine Exports Highlights Policy Divide

BIO chief calls US Defense Production Act ‘misguided’ as India seeks more COVID vaccines; America will donate AstraZeneca vaccine – just as soon as the FDA determines it was adequately manufactured.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS144333

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel